收稿日期: 2019-08-10
网络出版日期: 2019-12-19
基金资助
国家自然科学基金(81671604);国家自然科学基金(81302554);国家自然科学基金(31530020);北京市科技新星计划(Z181100006218044);北京大学临床医学+X青年项目-中央高校基本科研业务费(PKU2019LCXQ018)
Significance of anti-carbamylated fibrinogen antibodies in systemic lupus erythematosus
Received date: 2019-08-10
Online published: 2019-12-19
Supported by
Supported by the National Natural Science Foundation of China (81671604, 81302554, 31530020)(81671604);Supported by the National Natural Science Foundation of China (81671604, 81302554, 31530020)(81302554);Supported by the National Natural Science Foundation of China (81671604, 81302554, 31530020)(31530020);the Beijing Nova Program(Z181100006218044);the Fundamental Research Funds for Central Universities: Peking University Clinical Medcine Plus X-Young Scholars Project(PKU2019LCXQ018)
目的 探讨抗类瓜氨酸化抗体(anti-carbamylated fibrinogen antibodies, 抗CarP抗体)在系统性红斑狼疮(systemic lupus erythematosus,SLE)中的意义,SLE是否与类风湿关节炎(rheumatoid arthritis, RA)一样,存在大量针对类瓜氨酸的自身抗体,抗CarP抗体与关节损伤及疾病活动度高度相关。方法 利用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测105例确诊的SLE患者和73例健康对照者血清中抗CarP抗体水平,收集其他SLE相关临床和实验室数据,采用SPSS 24.0软件进行相应统计学分析。结果 SLE中存在抗CarP抗体,且明显高于健康对照组(P<0.05)。抗CarP抗体阳性组与阴性组SLE患者相比,在以下临床及实验室指标方面差异有统计学意义:病程、血沉(erythrocyte sedimentation rate,ESR)、C-反应蛋白(C-reactive protein,CRP)、类风湿因子(rheumatoid factor,RF)、抗心磷脂抗体、抗dsDNA抗体、D-二聚体、IgA、IgG、补体C3、补体C4、外周血红细胞计数和血红蛋白水平(P<0.05)。与SLE其他自身抗体相比,抗CarP抗体的阳性率(21.9%)高于抗Sm抗体(15.24%),与抗核糖体P蛋白抗体(22.86%)阳性率相似;在SLE特异性抗体阴性的患者中可检测到抗CarP抗体,其阳性率分别为: 抗Sm(-)组20.2%(18/89),抗dsDNA(-)组9.3%(4/43),抗核小体抗体(-)组12.5%(6/48)和抗核糖体P蛋白抗体(-)组20.9%(17/81)。而且,抗CarP抗体水平与病程、补体C3、补体C4、红细胞及血红蛋白呈明显负相关(P<0.05),与ESR、CRP、IgA、IgG、RF、抗心磷脂抗体、抗dsDNA抗体及D-二聚体呈明显正相关(P<0.05)。结论 SLE患者血清中抗CarP抗体水平升高,抗CarP抗体与SLE患者临床及实验室指标具有相关性。
关键词: 系统性红斑狼疮; 自身抗体; 类瓜氨酸化抗体(抗CarP抗体)
李英妮 , 相晓红 , 赵静 , 李云 , 孙峰 , 王红彦 , 贾汝琳 , 胡凡磊 . 抗类瓜氨酸化抗体在系统性红斑狼疮中的意义[J]. 北京大学学报(医学版), 2019 , 51(6) : 1019 -1024 . DOI: 10.19723/j.issn.1671-167X.2019.06.007
Objective: Antibodies against carbamylated protein (anti-CarP) were found to be a promising marker to evaluate joint damage and disease activity in patients with rheumatoid arthritis (RA). However, whether anti-CarP antibodies were present in systemic lupus erythematosus (SLE) remained ambiguity. We have therefore undertaken this study to assess the levels of serum anti-CarP antibodies and to evaluate their clinical value in SLE.Methods: Serum levels of antibodies against carbamylated-fibrinogen (anti-CarP) were measured by enzyme-linked immunosorbent assay (ELISA) in 105 SLE patients and 73 healthy controls. Other clinical and laboratory measurements of the SLE patients were collected from medical records. Data analyses between anti-CarP antibodies and other laboratory measurements were performed using SPSS software for Windows 24.0.Results: The levels of serum anti-CarP antibodies in the patients with SLE were significantly higher than those in the healthy controls (P<0.05). There were significant differences between the anti-CarP-positive group and anti-CarP-negative group in many clinical features. The disease duration, values of ESR, CRP, RF, anti-cardiolipin, anti-dsDNA, D-dipolymer, IgA and IgG were significantly higher in the anti-CarP-positive group compared with the negative group (P<0.05). Conversely, the values of complement 3, complement 4, peripheral blood RBC, and hemoglobin were significantly lower in anti-CarP-positive group than in the negative group(P<0.05). Moreover, the incidence of increase of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), D-dipolymer, decrease of peripheral blood RBC, hemoglobin, complement 3, complement 4, and positive rate of anti-dsDNA were significant different between the two groups(P<0.05). The positive rate of anti-CarP (21.9%) was higher than that of anti-Sm (15.24%), and close to anti-ribosomal P protein (22.86%) in our SLE patients. In addition, anti-CarP antibody was present in the SLE patients lacking the disease specific antibodies, including anti-Sm (anti-CarP positive rate 20.2%, 18/89), anti-dsDNA (anti-CarP positive rate 9.3%, 4/43), anti-nucleosome (anti-CarP positive rate 12.5%, 6/48), and anti-ribosomal P protein antibody (anti-CarP positive rate 20.9%, 17/81). Moreover, the high levels of anti-CarP antibodies were correlated with short disease duration, low C3, C4, RBC, and hemoglobin (P<0.05), high ESR, CRP, IgA, IgG, RF, anti-cardiolipin, anti-dsDNA, and D-dipolymer (P<0.05).Conclusion: The level of anti-CarP antibody was increased in the serum of patients with SLE. There were correlations between anti-CarP antibodies and clinical and laboratory indicators of SLE patients.
| [1] | Lee SJ, Silverman E, Bargman JM . The role of antimalarial agents in the treatment of SLE and lupus nephritis[J]. Nat Rev Nephrol, 2011,7(12):718-729. |
| [2] | Yaniv G, Twig G, Shor DB , et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients[J]. Autoimmun Rev, 2015,14(1):75-79. |
| [3] | Sherer Y, Gorstein A, Fritzler MJ , et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different anti-bodies found in SLE patients[J]. Semin Arthritis Rheum, 2004,34(2):501-537. |
| [4] | Betancur JF, Gómez-Puerta JA . Antinuclear antibodies mitotic patterns and their clinical associations [J/OL]. Ann Rheum Dis ( 2019-04-29)[2019-08-01]. |
| [5] | Bizzaro N, Villalta D, Giavarina D , et al. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis[J]. Autoimmun Rev, 2012,12(2):97-106. |
| [6] | Schreier SM, Steinkellner H, Jirovetz L , et al. S-carbamoylation impairs the oxidant scavenging activity of cysteine: its possible impact on increased LDL modification in uraemia[J]. Biochimie, 2011,93(4):772-777. |
| [7] | Gross ML, Piecha G, Bierhaus A , et al. Glycated and carbamylated albumin are more “nephrotoxic” than unmodified albumin in the amphibian kidney[J]. Am J Physiol Renal Physiol, 2011,301(3):476-485. |
| [8] | Trepanier DJ, Thibert RJ . Carbamylation of erythrocyte membrane aminophospholipids: an in vitro and in vivo study[J]. Clin Biochem, 1996,29(4):333-345. |
| [9] | Shi J, Knevel R, Suwannalai P , et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage[J]. Proc Natl Acad Sci USA, 2011,108(42):17372-17377. |
| [10] | Bergum B, Koro C, Delaleu N , et al. Antibodies against carbamylated proteins are present in primary Sj?gren’s syndrome and are associated with disease severity[J]. Ann Rheum Dis, 2016,75(8):1494-1500. |
| [11] | Scinocca M, Bell DA, Racapé M , et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides[J]. J Rheumatol, 2014,41(2):270-279. |
| [12] | López-Hoyos M, álvarez-Rodríguez L, Mahler M , et al. Anti-carbamylated protein antibodies in patients with ageing associated inflammatory chronic disorders[J]. Rheumatology (Oxford), 2016,55(4):764-766. |
| [13] | Ziegelasch M, van Delft MA, Wallin P , et al. Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two welldefined European cohorts[J]. Arthritis Res Ther, 2016,18(1):289. |
| [14] | Nakabo S, Yoshifuji H, Hashimoto M , et al. Anti-carbamylated protein antibodies are detectable in various connective tissue dis-eases[J]. J Rheumatol, 2017,44(9):1384-1388. |
| [15] | Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997,40(9):1725. |
| [16] | Turunen S, Koivula MK, Risteli L , et al. Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits[J]. Arthritis Rheum, 2010,62(11):3345-3352. |
| [17] | Shi J, van de Stadt LA, Levarht EWT , et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis[J]. Ann Rheum Dis, 2014,73(4):780-783. |
| [18] | Ceccarelli F, Perricone C, Colasanti T , et al. Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus[J]. Arthritis Res Ther, 2018,20(1):126 |
| [19] | Ceccarelli F, Perricone C, Cipriano E , et al. Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment[J]. Semin Arthritis Rheum, 2017,47(1):53-64. |
| [20] | Mastrangelo A, Colasanti T, Barbati C , et al. The role of post-translational protein modifications in rheumatological diseases: Focus on rheumatoid arthritis [J/OL]. J Immunol Res, 2015, 2015: 712490(2015-05-18)[2019-08-01]. |
/
| 〈 |
|
〉 |